Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Association of CAR T cell kinetics with outcomes after standard of care brexucabtagene autoleucel for relapsed/refractory Mantle Cell Lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

JWJason R. WestinESElizabeth J. ShpallSNSattva S. Neelapu

Discussion

Loading...

Member takes

Overview

Retrospective review found CAR T cell kinetics correlates with CRS and progression-free survival in mantle cell lymphoma patients, suggesting implications for treatment strategies.

Key Points

  • CAR-T therapy led to high response rates with 73% achieving complete response at 30 days post-infusion.
  • Median overall survival was 17 months following brexucabtagene autoleucel treatment in a cohort of 26 patients.
  • Use of flow cytometry-based assay assessed CAR T cell expansion and informed clinical outcomes.
  • A rise in ferritin was linked to increased high-grade cytokine release syndrome and neurotoxicity severity.],

Cite This Study

Westin et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6a2https://doi.org/10.1182/blood-2025-7092
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Acalabrutinib plus rituximab followed by brexucabtagene autoleucel for frontline treatment of high-risk Mantle Cell Lymphoma: The window-3 clinical trial2025 · 5 citations
  2. 2Two-year update of ZUMA-2 Cohort 3: Brexucabtagene autoleucel (Brexu-cel) in patients (pts) with relapsed/refractory mantle cell lymphoma (R/R MCL) who had not received prior Bruton tyrosine kinase inhibitor (BTKi) therapy2025
  3. 3Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma in asia: redefining the role of allogeneic haematopoietic stem cell transplantation2026
  4. 4Anti-CD19 CAR-T cells for Mantle Cell Lymphoma with central nervous system involvement: A study of the french descart registry.2025
  5. 5Brexucabtagene autoleucel (Brexucel) as a consolidation therapy in B-cell acute lymphoblastic leukemia (B-ALL) post HCVAD/minihcvd-inotuzumab-blinatumomab regimens: Initial Results of a prospective Phase 2 trial.2025 · 4 citations